Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Personalized Routine and Habit Integration to Support Medication Management (PRISM)

28. oktober 2026 opdateret af: Julie Lauffenburger, Brigham and Women's Hospital

A Randomized Controlled Trial of the Personalized Routine and Habit Integration to Support Medication Management Intervention (PRISM)

The objective of this study is to test a multidisciplinary care team behavioral intervention to enhance medication adherence among older adults with multiple chronic conditions (MCC). The Personalized Routine and Habit Integration to Support Medication Management (PRISM) intervention is a novel, scalable intervention delivered by pharmacists and occupational therapists (OTs) that aims to improve medication adherence by reducing regimen complexity and solidifying medication habits within daily routines. The goal of this randomized control trial is to evaluate the effectiveness and implementation of PRISM compared with enhanced usual care.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Massachusetts
      • Somerville, Massachusetts, Forenede Stater, 021250
        • Mass General Brigham
        • Kontakt:
          • Julie Lauffenburger, PharmD, PhD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

65 år og ældre (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. appointment in the past 18 months in the Galter-18 primary care practice
  2. ≥2 cardiovascular and/or metabolic chronic conditions documented in the EHR,
  3. ≥5 daily medications
  4. poor medication adherence ≥1 cardiovascular and/or metabolic medication using validated EHR-data algorithms
  5. English-speaking
  6. ≥65 years old

Exclusion Criteria:

  1. severe mental illness
  2. dementia
  3. dependent on others for medication management
  4. have received a pharmacist-led comprehensive medication review in the last 6 months

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: PRISM Arm

The PRISM arm will receive three sessions: 1) comprehensive medication management session with a clinical pharmacist, 2) an in-home visit with an occupational therapist (OT), and then 3) follow up phone call with OT.

The PRISM arm will receive three sessions: 1) comprehensive medication management session with a clinical pharmacist, 2) an in-home visit with an occupational therapist (OT), and then 3) follow up phone call with OT.

Eksperimentel: Enhanced usual care (EUC) arm

The EUC arm will receive a comprehensive medication management session with a clinical pharmacist.

The EUC arm will receive a comprehensive medication management session with a clinical pharmacist.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PDC (Continuous) - Cardiometabolic
Tidsramme: Through 6-months post-baseline

Medication adherence to cardio-metabolic pill-form daily medications including the following classes: ACE inhibitor, Angiotensin Receptor Blockers (ARBs), Beta-Blockers, Calcium Channel Blockers, Diuretics, Lipid-lowering, Metformin

Through 6-months post-baseline

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PDC (Continuous) - All
Tidsramme: Through 6-months post-baseline

Medication adherence to all daily prescription pill-form medications

Through 6-months post-baseline
PDC (Continuous) - Study-entering
Tidsramme: Through 6-months post-baseline

Medication adherence to study-entering medication i.e. the medciation that was identified during the eligibility screening process as having poor medication adherence.

Through 6-months post-baseline
Medication Adherence Report Scale 10-item (MARS-10)
Tidsramme: Through 3-months post-baseline

Self reported; medication ahderence to all prescriptoin daily medications

Through 3-months post-baseline
Regimen Knowledge (continuous)
Tidsramme: Through 3-months post-baseline

Participant knowledge of prescribed medications, including their purpose, dosage, and administration instructions using Medication Purpose & Dosage Identification Score (MPDS).

Through 3-months post-baseline
Regimen Complexity (continuous)
Tidsramme: Through 3-months post-baseline

Complexity of the participant's prescribed medication regime using Medication Regimen Complexity Index (MRCI).

Through 3-months post-baseline
Daily Routine (continuous)
Tidsramme: Through 3-months post-baseline

Daily activity patterns and routines, including the timing of activities throughout the day using a time diary.

Through 3-months post-baseline
Medication Habits (continuous)
Tidsramme: Through 3-months post-baseline

The extent to which medication-taking is performed automatically as a habitual behavior using Self-Report Behavioral Automaticity Index (SRBAI).

Through 3-months post-baseline
Problem Solving Skills (continuous)
Tidsramme: Through 3-months post-baseline

Participant ability to identify, address, and learn from problems affecting medication-taking and health management using Health Problem-Solving Scale (HPSS).

Through 3-months post-baseline

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. februar 2027

Primær færdiggørelse (Anslået)

1. februar 2028

Studieafslutning (Anslået)

1. maj 2028

Datoer for studieregistrering

Først indsendt

28. oktober 2026

Først indsendt, der opfyldte QC-kriterier

28. oktober 2026

Først opslået (Faktiske)

3. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2026P001972
  • 5P30AG064199-08 (U.S. NIH-bevilling/kontrakt)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .